SCHEMBL5767415

SCHEMBL5767415

COC(=O)c1ccc2cn(Cc3ccccc3)nc2c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 1/20 0.48
CFTR P13569 2/20 0.47
FGFR1 P11362 1/20 0.45
EHMT2 Q96KQ7 1/20 0.45
CD74 P04233 1/20 0.45
MIF P14174 1/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
TSHR P16473 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
TP53 P04637 1/20 0.44
GAA P10253 1/20 0.44
RAB9A P51151 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
DRD2 P14416 1/20 0.44
TBXA2R P21731 1/20 0.44
MAPT P10636 1/20 0.44
PTGDR2 Q9Y5Y4 1/20 0.43
PARP1 P09874 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25401651 0.90 THRB (0.53) CD74MIFTP53DRD2TBXA2R
SCHEMBL25403100 0.89 POLB (0.46) CD74MIFALDH1A1MEN1KMT2A
SCHEMBL25402742 0.89 FAAH (0.50) CD74MIFALDH1A1KMT2AGAA
SCHEMBL25402366 0.89 HDAC6 (0.49) MEN1KMT2AGAARAB9ADRD2
SCHEMBL25402905 0.89 GAA (0.49) TSHRMEN1KMT2ATP53GAA
SCHEMBL12706998 0.88 CA1 (0.47) ALDH1A1HPGDMEN1KMT2AGAA
SCHEMBL25403732 0.88 TP53 (0.47) HPGDMEN1KMT2ATP53GAA
SCHEMBL25401830 0.87 CYP19A1 (0.50) ALDH1A1TSHRTP53GAAMAPT
SCHEMBL25399737 0.87 CD74 (0.48) CD74MIFMEN1KMT2AADORA3
SCHEMBL25403016 0.87 MRGPRX4 (0.46) CD74MIFALDH1A1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250197369-A1 NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME SOOKMYUNG WOMEN'S UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) 2025-06-19 US disclosed
EP-4494640-A1 NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Sookmyung Women's University Industry-Academic Cooperation Foundation (KR) 2025-01-22 EP disclosed
CN-119212701-A Novel histone deacetylase heterocycle inhibitor and pharmaceutical composition containing the same 淑明女子大学校 产学协力团 2024-12-27 CN disclosed
WO-2023177250-A1 NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 숙명여자대학교산학협력단 2023-09-21 WO disclosed
US-8383662-B2 Bicyclic heteroaryl compounds NATIONAL CHIAO TUNG UNIVERSITY (TW) 2013-02-26 US disclosed
US-8383662-B2 Bicyclic heteroaryl compounds NATIONAL CHIAO TUNG UNIVERSITY (TW) 2013-02-26 US disclosed
US-20110082143-A1 Bicyclic Heteroaryl Compounds NATIONAL TAIWAN UNIVERSITY (TW) 2011-04-07 US disclosed
US-20110082143-A1 Bicyclic Heteroaryl Compounds NATIONAL TAIWAN UNIVERSITY (TW) 2011-04-07 US disclosed
US-7825261-B2 Indazole compounds NATIONAL TAIWAN UNIVERSITY (TW) 2010-11-02 US disclosed
US-7825261-B2 Indazole compounds NATIONAL TAIWAN UNIVERSITY (TW) 2010-11-02 US disclosed
WO-2008070599-A1 INDAZOLE COMPOUNDS SUN CHUNG-MING (US) 2008-06-12 WO disclosed
US-20080132501-A1 INDAZOLE COMPOUNDS NATIONAL TAIWAN UNIVERSITY (TW) 2008-06-05 US disclosed
US-20080132501-A1 INDAZOLE COMPOUNDS NATIONAL TAIWAN UNIVERSITY (TW) 2008-06-05 US disclosed
EP-1615636-A1 BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS PFIZER INC. (US) 2006-01-18 EP disclosed
WO-2004089366-A1 BICYCLIC COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS PFIZER JAPAN, INC. (JP) 2004-10-21 WO disclosed
US-20040204409-A1 Bicyclic compounds as NR2B receptor antagonists ANDO KAZUO (JP) 2004-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250197369-A1 NOVEL HETEROCYCLIC INHIBITOR FOR HISTONE DEACETYLASE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME HDAC1, HDAC6, HDAC5 P2RX7 3939/4885CFTR 1794/4885FGFR1 612/4885
US-20110082143-A1 Bicyclic Heteroaryl Compounds SDHA, CYP2F1, PAICS P2RX7 4432/4885CFTR 3749/4885FGFR1 814/4885
US-20080132501-A1 INDAZOLE COMPOUNDS CYP1B1, IDH3B, IDH2 P2RX7 3105/4885CFTR 1068/4885FGFR1 657/4885
US-20040204409-A1 Bicyclic compounds as NR2B receptor antagonists GRIN1, GRIN2B, GRIN2A P2RX7 137/4885CFTR 3524/4885FGFR1 511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.